Jiangsu Aoyang Health Industry Co. (002172) Fair Value & Analysis
Basic Materials · CN · Market cap 2.4B CNY
Fair value as of: Jul 22, 2026
From 15 valuation models · updated 20 days ago
Share price +14.8% over the past month.
Below-average quality, and screening another 76% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥1.15). The favourable scenario is already priced in.
- Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥2.31 – ¥7.10 · fair‑value band ¥0.6900 – ¥1.15 · the ¥3.41 price screens above the ¥0.8200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Jiangsu Aoyang Health Industry Co. (002172) currently trades at ¥3.41, while our model-based Fair Value estimate is ¥0.8200, implying the stock looks roughly 76.0% overvalued today. The Quality Score stands at 45/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Jiangsu Aoyang Health Industry Co. generated revenue of 1.8B CNY at a net margin of 1.6%. Revenue declined 10.0% year over year. It earns a return on equity of 19.0%. Net debt stands at 332M CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥0.6900 (bear case) to ¥1.15 (bull case); at ¥3.41, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 34% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -46% fair-value upside, at -76%, 002172 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (¥1.61) versus Asset-Based (¥0.1500). Highest evidence: Residual Income (76).
Notify me when 002172 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jiangsu Aoyang Health Industry Co.ltd. engages in the production and sale of viscose chemical fibers in China and internationally.
Full company description
Jiangsu Aoyang Health Industry Co.ltd. engages in the production and sale of viscose chemical fibers in China and internationally. It engages in investment and development in the health industry; manufacture and sale of viscose fiber and viscose fiber products, degradable fibers, and functional fibers; sale of textile raw materials, textiles, and chemical products; steam heat supply; power production; and self-operated and agency of the import and export of commodities and technologies. The company also offers health management and wellness and pharmaceutical logistics services, as well as distributes pharmaceutical products. In addition, it is involved in the wholesale of pharmaceuticals, medical devices, and other products; processing, purchasing, selling, and cultivating of Chinese medicinal materials; rehabilitation medical services; medical aesthetics; pharmaceutical retail; research and experimental development; and provision of maternal and child health consultation services, as well as scientific research and technical services. The company was formerly known as Jiangsu Aoyang Technology Corporation Limited. and changed its name to Jiangsu Aoyang Health Industry Co.ltd. in September 2018. Jiangsu Aoyang Health Industry Co.ltd. was incorporated in 2001 and is headquartered in Zhangjiagang, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jiangsu Aoyang Health Industry Co. reported revenue of ¥1.8B in FY2025 versus ¥1.4B in FY2021, a compound +6.0%/yr. Reported net income was ¥41.3M in FY2025.
002172 screens 76% overvalued. Compare with BASF SE →
Peer Group
Chemicals · 333 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| BASF SE BASN | 1,034 MXN | 532.13 MXN | -49% |
| Ningxia Baofeng Energy Group 600989 | ¥20.32 | ¥20.17 | -1% |
| Zhejiang Juhua Co 600160 | ¥42.85 | ¥23.35 | -46% |
| PT Barito Pacific Tbk, BRPT | 1,690 IDR | 1,628 IDR | -4% |
| LG Chem, Ltd 051910 | 260,500 KRW | 587,755 KRW | +126% |
| Formosa Chemicals & Fibre Corporation 1326 | 66.10 TWD | 6.79 TWD | -90% |
| PTT Global Chemical Public Company PTTGC | 35.50 THB | 18.21 THB | -49% |
| 542812 542812 | ₹4,369 | ₹791.05 | -82% |
| Indorama Ventures Public Company IVL | 24.50 THB | 17.95 THB | -27% |
| Navin Fluorine International Limited NAVINFLUOR | ₹8,650 | ₹2,146 | -75% |
Compare Jiangsu Aoyang Health Industry Co. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Jiangsu Aoyang Health Industry Co. (002172) overvalued or undervalued?
What is the fair value of 002172?
What is the quality score of 002172?
What is the revenue of Jiangsu Aoyang Health Industry Co. (002172)?
What is the net profit margin of 002172?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jiangsu Aoyang Health Industry Co. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.